CASI (CASI Pharmaceuticals) EBIT per Share : $-2.28 (TTM As of Sep. 2024)

View and export this data going back to 1996. Start your Free Trial

What is CASI Pharmaceuticals EBIT per Share?

CASI Pharmaceuticals's EBIT per Share for the three months ended in Sep. 2024 was $-0.53. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.28.

During the past 3 years, the average EBIT per Share Growth Rate was 14.40% per year. During the past 5 years, the average EBIT per Share Growth Rate was 13.10% per year. During the past 10 years, the average EBIT per Share Growth Rate was -1.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for CASI Pharmaceuticals's EBIT per Share or its related term are showing as below:

CASI' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -62.4 Med: 14.2 Max: 50.6
Current: 14.4

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of CASI Pharmaceuticals was 50.60% per year. The lowest was -62.40% per year. And the median was 14.20% per year.

CASI's 3-Year EBIT Growth Rate is ranked better than
66.75% of 1248 companies
in the Biotechnology industry
Industry Median: 2.8 vs CASI: 14.40

CASI Pharmaceuticals's EBIT for the three months ended in Sep. 2024 was $-8.09 Mil.

CASI Pharmaceuticals EBIT per Share Historical Data

The historical data trend for CASI Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CASI Pharmaceuticals EBIT per Share Chart

CASI Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-4.13

-3.02

-2.59

-1.94

-1.89

CASI Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															-0.39	-0.36	-0.69	-0.71	-0.53

CASI Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

CASI Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-25.28	/	13.360
=	-1.89

CASI Pharmaceuticals's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.085	/	15.294
=	-0.53

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.28

CASI Pharmaceuticals (NAS:CASI) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

CASI Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of CASI Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CASI Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (NAS:CASI) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 81, Jianguo Road, Room 1701-1703, Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025

Website

https://www.casipharmaceuticals.com

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

Executives

James Huang	director	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Wei-wu He	director, 10 percent owner, officer: Chairman and CEO	ENTREMED, INC., 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Weihao Xu	officer: Chief Financial Officer	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Larry Zhang	officer: President	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Shrotriya Rajesh C Md	director	157 TECHNOLOGY DRIVE, IRVINE CA 92618
Salisbury Franklin Cary Jr	director	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Yue Alexander Wu	director	C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
Wealth Strategy Holding Ltd	10 percent owner	LEVEL 12, INTERNATIONAL COMMERCE CENTRE, 1 AUSTIN ROAD WEST, HONG KONG K3 HK
Alexander A Zukiwski	officer: Chief Medical Officer	200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
George Chi	officer: Chief Financial Officer	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Dapeng Li	10 percent owner	BUILDING 1037,XIHU GOLF,, ZHIGANG ROAD 200, HANGZHOU, ZHEJANG F4 310008
Idg-accel China Growth Fund Iii L.p.	10 percent owner	UNIT 5505, 55TH FLOOR, THE CENTER, 99 QUEEN'S ROAD K3 00000
Spectrum Pharmaceuticals Inc	10 percent owner	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Sparkle Byte Ltd	10 percent owner	P.O. BOX 957, OFFSHORE INCORPORATIONS CENTRE ROAD TOWN, TORTOLA D8 00000
Ken Ren	director, officer: CEO and Director	3RD FL, BOROUGH A, BLOCK A, NO. 181 SOUTH TAIBAI ROAD, XI'AN, SHAANXI PROVINCE F4 710065